Evidence map›Paper›PMID 33357038›Full record

ArticleJournal of biomolecular structure & dynamics2022

Design and

Mücahit Özdemir, Baybars Köksoy, Deniz Ceyhan, Koray Sayın, Erol Erçağ, Mustafa Bulut, Bahattin Yalçın

Open access · greenAbstract read
In one paragraph

Article in Journal of biomolecular structure & dynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Current drug discovery technologies · 2024
    Article
  4. Antiviral Effects of Secondary Metabolites fromPlants (Basel, Switzerland) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Research progress of coumarins and their derivatives in the treatment of diabetes.Journal of enzyme inhibition and medicinal chemistry · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mücahit ÖzdemirDepartment of Chemistry, Marmara University, Istanbul, Turkey.ORCID 0000-0002-0840-4953
Baybars KöksoyDepartment of Chemistry, Bursa Technical University, Bursa, Turkey.ORCID 0000-0001-7939-5380
Deniz CeyhanDepartment of Chemistry, Tekirdağ Namık Kemal University, Tekirdağ, Turkey.ORCID 0000-0003-1811-3858
Koray SayınDepartment of Chemistry, Sivas Cumhuriyet University, Sivas, Turkey.ORCID 0000-0001-6648-5010
Erol ErçağDepartment of Chemistry, Tekirdağ Namık Kemal University, Tekirdağ, Turkey.ORCID 0000-0003-4927-2405
Mustafa BulutDepartment of Chemistry, Marmara University, Istanbul, Turkey.ORCID 0000-0001-9598-2649
Bahattin YalçınDepartment of Chemistry, Marmara University, Istanbul, Turkey.ORCID 0000-0003-4448-1101
Marmara University · TRTekirdağ Namık Kemal University · TRBursa Technical University · TRSivas Cumhuriyet Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel coronavirus (SARS-CoV-2) causes severe acute respiratory syndrome and can be fatal. In particular, antiviral drugs that are currently available to treat infection in the respiratory tract have been experienced, but there is a need for new antiviral drugs that are targeted and inhibit coronavirus. The antiviral properties of organic compounds found in nature, especially coumarins, are known and widely studied. Coumarins, which are also metabolites in many medicinal drugs, should be investigated as inhibitors against coronavirus due to their pharmacophore properties (low toxicity and high pharmacokinetic properties). The easy addition of substituents to the chemical structures of coumarins makes these structures unique for the drug design. This study focuses on factors that increase the molecular binding and antiviral properties of coumarins. Molecular docking studies have been carried out to five different proteins (Spike S1-subunit, NSP5, NSP12, NSP15, and NSP16) of the SARS-CoV-2 and two proteins (ACE2 and VKORC1) of human. The best binding scores for 17 coumarins were determined for NSP12 (NonStructural Protein-12). The highest score (-10.01 kcal/mol) in the coumarin group is 2-morpholinoethan-1-amine substituted coumarin. Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) analyses of selected ligand-protein complexes were performed. The binding energies in each 5 ns were calculated and it was found that the interaction between ligand and target protein were stable.Communicated by Ramaswamy H. Sarma.

Indexed as

Antiviral AgentsCoumarinsSARS-CoV-2COVID-19 Drug TreatmentDrug DesignHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationVitamin K Epoxide ReductasesAntiviral AgentsCoumarinsLigandsVitamin K Epoxide ReductasesVKORC1 protein, humanCoronaviruscoumarindrug designMM-PBSAmolecular dockingSARS-CoV-2

Identifiers

PMID33357038
PMCPMC7784838
OpenAlexW3116740748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.